CABA Cabaletta Bio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1759138 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-19.5%
TTM EPS YoY44.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-89.5%
ROA-72.0%
ROIC (approx.)-479.6%
Asset turnover—
Leverage & solvency
Liabilities / assets15.6%
Debt / equity0.00x
Current ratio6.55x
Interest coverage-87.26x
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $47.14M | $44.43M | $37.35M | $36.19M | $39.82M | $37.64M | $29.02M | $25.53M |
| SG&A expense | $7.56M | $7.59M | $6.94M | $6.42M | $6.76M | $8.27M | $8.12M | $8.25M |
| Operating income | -$54.71M | -$52.02M | -$44.30M | -$42.61M | -$46.59M | -$45.91M | -$37.14M | -$33.78M |
| Interest expense | $511,000 | $517,000 | $636,000 | $555,000 | $584,000 | $571,000 | $294,000 | $748,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$53.05M | -$51.02M | -$43.52M | -$41.92M | -$44.87M | -$45.13M | -$35.94M | -$32.59M |
| EBITDA | -$54.36M | -$51.65M | -$43.96M | -$42.26M | -$46.24M | -$45.44M | -$36.65M | -$33.32M |
| EPS (basic) | -0.28 | -0.34 | -0.39 | — | -0.44 | -0.73 | -0.71 | — |
| EPS (diluted) | -0.28 | -0.34 | -0.39 | — | -0.44 | -0.73 | -0.71 | — |
| Weighted avg. shares (diluted) | 186.78M | 151.16M | 112.03M | — | 102.26M | 61.88M | 50.74M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $299.38M | $225.10M | $116.64M | $82.98M | $60.21M | $145.61M | $131.83M | $163.96M |
| Short-term investments | $0 | $0 | $0 | $50.62M | $99.72M | $49.07M | — | $0 |
| Current assets | $309.85M | $231.03M | $122.32M | $138.87M | $164.56M | $198.41M | $134.60M | $166.68M |
| PP&E, net | $1.01M | $1.48M | $1.58M | $1.92M | $2.06M | $2.37M | $2.64M | $2.74M |
| Total assets | $336.49M | $256.73M | $148.15M | $165.08M | $189.76M | $224.50M | $165.14M | $185.05M |
| Current liabilities | $47.33M | $39.91M | $41.51M | $50.15M | $45.73M | $41.54M | $33.99M | $27.09M |
| Total liabilities | $52.57M | $46.13M | $44.84M | $53.03M | $50.29M | $46.02M | $43.59M | $32.71M |
| Shareholders' equity | $283.92M | $210.59M | $103.31M | $112.05M | $139.47M | $178.48M | $121.55M | $152.34M |
| Shares outstanding | — | — | — | 100.48M | 96.27M | 91.45M | — | 50.74M |
| Cash flow statement | ||||||||
| Operating cash flow | -$42.74M | -$41.51M | -$42.56M | -$35.34M | -$34.51M | -$30.43M | -$30.80M | -$23.12M |
| Capital expenditure | $142,000 | $0 | $0 | $205,000 | $78,000 | $161,000 | $785,000 | $376,000 |
| Free cash flow | -$42.89M | -$41.51M | -$42.56M | -$35.55M | -$34.59M | -$30.59M | -$31.59M | -$23.50M |
| Investing cash flow | -$142,000 | $0 | $50.96M | $49.80M | -$50.08M | -$49.20M | -$785,000 | $12.12M |
| Financing cash flow | $117.19M | $149.99M | $25.27M | $8.33M | -$806,000 | $93.37M | -$552,000 | $4.37M |
| Depreciation & amortization | $347,000 | $371,000 | $337,000 | $348,000 | $345,000 | $468,000 | $485,000 | $468,000 |
| Stock-based compensation | $5.26M | $5.50M | $5.26M | $4.26M | $5.82M | $5.71M | $5.16M | $5.41M |
Free plan shows the latest 8 periods; Pro shows all 33 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.